Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $8.00 Price Target at Guggenheim

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective lowered by Guggenheim from $12.00 to $8.00 in a research note issued to investors on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities research analysts have also weighed in on the company. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday. Finally, Oppenheimer reiterated an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Stock Down 12.2 %

Shares of NASDAQ:ZNTL opened at $3.47 on Friday. The company has a market capitalization of $247.27 million, a price-to-earnings ratio of -1.39 and a beta of 1.74. The company has a 50 day moving average of $3.42 and a two-hundred day moving average of $5.38. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.76 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its holdings in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after acquiring an additional 585,644 shares during the last quarter. Decheng Capital LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after purchasing an additional 970,859 shares during the last quarter. Verition Fund Management LLC boosted its position in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Primecap Management Co. CA grew its stake in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after buying an additional 265,690 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after buying an additional 399,745 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.